Ocular side effects of systemic medications

Background: Systemic medications, which are crucial for managing a wide range of diseases from hypertension and diabetes to infections and cancers, can induce substantial ocular side effects. These effects impact visual function and quality of life, necessitating awareness and monitoring by healthcare professionals. The current review summarizes the range and mechanisms of these ocular toxicities. Methods: This narrative review was derived from a targeted literature search using major electronic databases including PubMed/MEDLINE, Embase, Scopus, and Google Scholar. Keywords related to ocular side effects of systemic medications were utilized to identify relevant studies published from January 1, 2000, to December 30, 2024. The included articles pertained to ocular manifestations of systemic drug use, their mechanisms of toxicity, and associated management strategies. Results: This study identified notable ocular side effects related to various systemic medications. Amiodarone was consistently linked to corneal deposits and colored halos, prompting recommendations for regular eye examinations. Isotretinoin was frequently associated with dry mucous membranes and blepharoconjunctivitis. Chloroquine and hydroxychloroquine were found to cause corneal changes and irreversible retinal damage with prolonged use. Studies of allopurinol presented conflicting evidence regarding its relationship with cataract risk. Corticosteroid use was associated with cataract formation and potential elevation of intraocular pressure. Ethambutol has been identified as a potential cause of optic neuritis. Topiramate was linked to acute angle-closure glaucoma, particularly early in treatment. Anticholinergic drugs can impact various parts of the eye. They cause ciliary muscle relaxation, leading to temporary blurred vision. This loss of accommodation, also known as “iatrogenic presbyopia,” results from paralysis of the ciliary muscle. Phosphodiesterase type 5 inhibitors, such as sildenafil, may cause pupil dilation, redness, dryness, blurred vision, and temporary cyanopsia. Additionally, patients taking vigabatrin may experience progressive constriction of the visual fields, necessitating regular visual field assessments. Epidemiological studies indicate that approximately 15% of patients taking systemic medications experience dry eye syndrome. These findings underscore the diverse range and impact of drug-induced ocular toxicities. However, vigilant monitoring and prompt management can help mitigate vision-threatening complications and preserve patients’ visual health. Addressing these ocular side effects requires strong interdisciplinary communication among ophthalmologists, optometrists, primary care physicians, and other specialists. Conclusions: The wide range of ocular manifestations of systemic medication use emphasizes the importance of monitoring patients for these side effects. Collaborative management by eye care professionals and prescribing physicians is vital to mitigate risks. Further research must focus on the mechanisms of drug-induced ocular toxicity and developing effective preventive measures.